Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 10;24(1):105.
doi: 10.1186/s13063-023-07125-2.

The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial

Lynette Hammond Gerido  1 , Jennifer J Griggs  2   3   4 , Ken Resnicow  2   3 , Kelley M Kidwell  2   3 , Emerson Delacroix  2   5 , Sarah Austin  3 , Erika N Hanson  5 , Elizabeth Bacon  5 , Erika Koeppe  3   5 , Stefanie Goodall  3 , Matthew Demerath  3 , Elizabeth A Rizzo  3 , Shayna Weiner  3 , Sarah T Hawley  3 , Wendy R Uhlmann  4   5 , J Scott Roberts  2 , Elena M Stoffel  3   4   5
Affiliations

The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial

Lynette Hammond Gerido et al. Trials. .

Abstract

Background: Although most cancers are sporadic, germline genetic variants are implicated in 5-10% of cancer cases. Clinical genetic testing identifies pathogenic germline genetic variants for hereditary cancers. The Michigan Genetic Hereditary Testing (MiGHT) study is a three-arm randomized clinical trial that aims to test the efficacy of two patient-level behavioral interventions on uptake of cancer genetic testing.

Methods: The two interventions being tested are (1) a virtual genetics navigator and (2) motivational interviewing by genetic health coaches. Eligible participants are adults with a diagnosis of breast, prostate, endometrial, ovarian, colorectal, or pancreatic cancer who meet the National Comprehensive Cancer Network (NCCN) criteria for genetic testing. Participants are recruited through community oncology practices affiliated with the Michigan Oncology Quality Consortium (MOQC) and have used the Family Health History Tool (FHHT) to determine testing eligibility. The recruitment goal is 759 participants, who will be randomized to usual care or to either the virtual genetics navigator or the motivational interviewing intervention arms. The primary outcome will be the proportion of individuals who complete germline genetic testing within 6 months.

Discussion: This study addresses patient-level factors which are associated with the uptake of genetic testing. The study will test two different intervention approaches, both of which can help address the shortage of genetic counselors and improve access to care.

Trial registration: This study has been approved by the Institutional Review Board of the University of Michigan Medical School (HUM00192898) and registered in ClinicalTrials.gov (NCT05162846).

Keywords: Cancer; Genetic counseling; Genetic testing; Motivational interviewing; RCT; eHealth.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med. 2005;7(1):1. doi: 10.1097/01.GIM.0000151155.36470.FF. - DOI - PubMed
    1. Abul-Husn NS, et al. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 2019;12(1):2. doi: 10.1186/s13073-019-0691-1. - DOI - PMC - PubMed
    1. Maratt JK, Stoffel E. Identification of lynch syndrome. Gastrointest. Endosc Clin. 2022;32(1):45–58. doi: 10.1016/j.giec.2021.09.002. - DOI - PubMed
    1. Giri VN, et al. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019;79(4):333–339. doi: 10.1002/pros.23739. - DOI - PubMed
    1. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J. Med. 2007;357(2):154–162. doi: 10.1056/NEJMcp071286. - DOI - PubMed

Publication types

Associated data